Estrogen receptor-positive, ErbB2 (formerly HER2/neu)-negative (ER+ErbB2-) breast cancer is typically endocrine therapy sensitive and poorly responsive to systemic chemotherapy. This evidence concerns the gene ESR1 and breast cancer.